College Hill Life Sciences Adds To Its Portfolio with 10 New Clients
11 September 2013, London, Manchester, Munich, Boston, Sydney, Melbourne: The Life Sciences team of College Hill, part of the international business communications consultancy, College Group, continues to expand its portfolio with 10 additional client wins during the last three months. New client mandates span the Consultancy’s offering from fully retained services to branding and ad hoc projects.
Scotland-based Clinical-stage specialty biotechnology company Novabiotics has retained College Hill to provide strategic counsel and communications support. Novabiotics is focused on the development of first-in-class anti-infective technology for difficult-to-treat, medically unmet fungal and bacterial conditions.
A number of companies in Germany, Canada, Australia and the UK have brought in the College Hill team to support messaging and PR projects including:
Caprotec, a Berlin-based company who has developed a ground-breaking, proprietary technology to reduce the complexity of biological mixtures and samples through protein isolation.
Cytotools, a company developing pharmaceutical and medical products in the fields of dermatology, urology, cardiovascular diseases, and cancer, based in Germany.
Canadian-based gIcare Pharma, developers of innovative medicines that enable sedation-free colonoscopy, and a Forbion Capital Partners investee company.
UK-based Oxford Pharmascience, a specialist pharmaceutical technology company developing and licensing solutions to add value to off patent and soon to be off patent drugs.
TranScrip Partners, a rapidly growing contract organisation that supports biopharmaceutical product development and life cycle management.
Imugene, based in Melbourne, is using drug delivery technology to improve the efficacy and safety of diverse number of existing prescription and over the counter medicines. The technology enables the active ingredient of the drug to be absorbed straight into the blood stream.
SYNthesis med chem, a provider of small molecule drug discovery services with a focus on the provision of world class medicinal and synthetic chemistry, based in the UK.
The Life Sciences design team has been signed up by two new companies in Australia, both Brandon Capital portfolio companies:
A new website has been designed and launched for Otifex Therapeutics, who investigating a new treatment for the most common cause of acquired hearing loss in childhood – www.otifex.com
For start-up company Protego, a medical device company that has developed a fully flexible surgical guard to protect the split edges of the breastbone during cardiac surgery, we have developed a corporate identity and logo.
“It’s good to see that we are winning new clients and mandates from companies that are spread across our global bases, and that the breadth of our offering is being appreciated in the spectrum of communications services for which we are being sought out” commented Sue Charles, Managing Partner, College Hill Life Sciences.
For further information:
Managing Partner, Life Sciences
+44 (0)20 7457 2020